Novartis, already a strategic partner of SomaLogic, was an investor in a $16.5m round raised by the clinical diagnostics company.

Medtech spin-out of Texas A&M University 3Scan secures $6.7m series A.

Bern spin-out Synthena drives promising clinical trials into duchenne muscular dystrophy.

Genomic Health-backed Invitae, which is developing a new genetic testing system, would raise more than $80m if it floats at the top of its range.

The corporates will invest the money in medical device technology companies graduating from the incubator over an eight-year period.

The genome mapping company has increased the size of a Novartis and Legend-backed round, which first closed in November, by more than $15m.

The pharmaceutical company, which is developing treatments for retinal conditions, is set to float above its range.

Arkansas University spin-out Intervexion raises $14.5m in federal backing for meth addiction-breaking drug.

Novartis, Johnson & Johnson and Consort Medical all returned to invest in the company's series C round as it looks to commercialise its diagnostic testing system.

DNA-based therapeutics developer EnGene raised the money in a Pharmstandard-backed series B round that increased its overall funding to more than $31m.